Cite

HARVARD Citation

    Kaufman, P. et al. (n.d.). Balixafortide (a CXCR4 antagonist) plus eribulin in HER2-negative metastatic breast cancer (MBC): A Phase I open-label trial. European journal of cancer. pp. S117-S118. [Online]. 
  
Back to record